Literature DB >> 23228402

"Reverse Blalock-Taussig shunt": application in single ventricle hybrid palliation.

Kenji Baba1, Osami Honjo, Rajiv Chaturvedi, Kyong-Jin Lee, Glen Van Arsdell, Christopher A Caldarone, Lee N Benson.   

Abstract

OBJECTIVE: Retrograde aortic arch malperfusion after ductal stenting can be life-threatening after univentricular hybrid palliation. Arch perfusion can be maintained with a main pulmonary artery to innominate artery shunt placed during the stage I procedure: a "reverse Blalock-Taussig shunt."
METHODS: A retrospective review of 37 infants who underwent hybrid palliation from January 2004 to March 2010 was performed. The infants were divided into 2 groups, those with (group I, n = 16) and those without (group II, n = 21) a reverse Blalock-Taussig shunt.
RESULTS: At the initial palliation, no differences were found in the demographics, systolic or diastolic pressures, or ventricular or atrioventricular valve function between the 2 groups. Group I had more infants with aortic atresia (P < .01) and smaller ascending aortas (P < .01). Before stage II, the retrograde aortic Doppler flow velocity increased in group I (P < .01) and was unchanged in group II. The reintervention rates before stage II were similar between the 2 groups. Before stage II, the ventricular end-diastolic pressure, left and right pulmonary artery pressures and diameters, and mixed venous and arterial saturations were similar between the 2 groups. The complication rates between the 2 groups were not significantly different, although a nonsignificant trend toward more neurologic complications was noted in group I. The Kaplan-Meier survival estimate at 1 year was similar between the 2 groups (63% for group I vs 71% for group II).
CONCLUSIONS: The presence of a reverse Blalock-Taussig shunt was not associated with more adverse events than those without. Gradual retrograde arch obstruction occurs commonly in palliated infants with aortic atresia. A reverse Blalock-Taussig shunt might play an important role to address the potential of retrograde obstruction, augmenting arch blood flow.
Copyright © 2013 The American Association for Thoracic Surgery. Published by Mosby, Inc. All rights reserved.

Entities:  

Keywords:  20; 26.1.1; AVVR; BT; Blalock-Taussig; ECMO; PA; PVR; atrioventricular valve regurgitation; extracorporeal membrane oxygenation; pulmonary artery; pulmonary valve regurgitation; revBT; reverse BT

Mesh:

Year:  2012        PMID: 23228402     DOI: 10.1016/j.jtcvs.2012.11.029

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  6 in total

1.  Stage 1 hybrid palliation for hypoplastic left heart syndrome--assessment of contemporary patterns of use: an analysis of The Society of Thoracic Surgeons Congenital Heart Surgery Database.

Authors:  Tara Karamlou; David Overman; Kevin D Hill; Amelia Wallace; Sara K Pasquali; Jeffrey P Jacobs; Marshall L Jacobs; Christopher A Caldarone
Journal:  J Thorac Cardiovasc Surg       Date:  2014-08-14       Impact factor: 5.209

2.  High risk HLHS: hybrid approach yes, but how does it work?

Authors:  Dietmar Schranz
Journal:  Transl Pediatr       Date:  2018-07

Review 3.  Current Therapy for Hypoplastic Left Heart Syndrome and Related Single Ventricle Lesions.

Authors:  Richard G Ohye; Dietmar Schranz; Yves D'Udekem
Journal:  Circulation       Date:  2016-10-25       Impact factor: 29.690

Review 4.  Hypoplastic Left Heart: Stage-I Will be Performed Interventionally, Soon.

Authors:  Dietmar Schranz; Anoosh Esmaeili; Hakan Akintuerk
Journal:  Pediatr Cardiol       Date:  2021-04-19       Impact factor: 1.655

Review 5.  Decision-Making for Surgery in the Management of Patients with Univentricular Heart.

Authors:  Ryan Robert Davies; Christian Pizarro
Journal:  Front Pediatr       Date:  2015-07-27       Impact factor: 3.418

6.  Apples to oranges: Making sense of hybrid palliation for hypoplastic left heart syndrome.

Authors:  Travis J Wilder; Christopher A Caldarone
Journal:  JTCVS Open       Date:  2020-10-15
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.